InflaRx N.V. (IFRX)
Market Cap | 101.87M |
Revenue (ttm) | 107,746 |
Net Income (ttm) | -44.83M |
Shares Out | 58.88M |
EPS (ttm) | -0.77 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 62,911 |
Open | 1.680 |
Previous Close | 1.730 |
Day's Range | 1.660 - 1.750 |
52-Week Range | 1.140 - 4.350 |
Beta | 1.20 |
Analysts | Strong Buy |
Price Target | 13.50 (+680.35%) |
Earnings Date | Aug 8, 2024 |
About IFRX
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflamma... [Read more]
Analyst Forecast
According to 2 analysts, the average rating for IFRX stock is "Strong Buy." The 12-month stock price forecast is $13.5, which is an increase of 680.35% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/a/e/press4-2492589.jpg)
InflaRx's GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)
JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today ...
![](https://cdn.snapi.dev/images/v1/q/x/press1-2464188.jpg)
InflaRx Hosts R&D Event Highlighting the Promise of INF904
JENA, Germany, June 05, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today hosted a v...
![](https://cdn.snapi.dev/images/v1/i/j/press10-2442276.jpg)
InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators
JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data pr...
![](https://cdn.snapi.dev/images/v1/g/l/press16-2417712.jpg)
InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update
JENA, Germany, May 08, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced fina...
![](https://cdn.snapi.dev/images/v1/1/g/press17-2387712.jpg)
InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event
JENA, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced tha...
![](https://cdn.snapi.dev/images/v1/h/1/press20-2334839.jpg)
InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans
JENA, Germany, March 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its...
![](https://cdn.snapi.dev/images/v1/p/3/conf16-2330629.jpg)
InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024
JENA, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced...
![](https://cdn.snapi.dev/images/v1/o/q/press20-2288204.jpg)
InflaRx Appoints Jan Medina as Head of Investor Relations
JENA, Germany, Feb. 22, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced ...
![](https://cdn.snapi.dev/images/v1/1/x/press19-2244147.jpg)
InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients
ANN ARBOR, Mich., Jan. 25, 2024 (GLOBE NEWSWIRE) -- InflaRx Pharmaceuticals Inc., a subsidiary of InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by ...
![](https://cdn.snapi.dev/images/v1/5/g/press2-2216010.jpg)
InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904
JENA, Germany, Jan. 04, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics targeting the complement system, announced today topline...
![](https://cdn.snapi.dev/images/v1/z/i/press14-2141215.jpg)
InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum
JENA, Germany, Nov. 06, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that th...
![](https://cdn.snapi.dev/images/v1/x/4/press13-2132523.jpg)
InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update
JENA, Germany, Nov. 01, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics targeting the complement system, announced today financi...
![](https://cdn.snapi.dev/images/v1/g/g/press4-2057106.jpg)
InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904
JENA, Germany, Sept. 11, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics targeting the complement system, announced today its to...
![](https://cdn.snapi.dev/images/v1/q/d/press11-2042709.jpg)
InflaRx's Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)
JENA, Germany, Aug. 30, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that th...
![](https://cdn.snapi.dev/images/v1/d/5/press1-2016870.jpg)
InflaRx Reports Second Quarter 2023 Financial Results & Operating Update
• Quarter highlighted by the Emergency Use Authorization (EUA) and commercial launch of Gohibic (vilobelimab) in the United States
![](https://cdn.snapi.dev/images/v1/e/p/press6-1951073.jpg)
InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer
JENA, Germany, June 28, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company commercializing and developing anti-inflammatory therapeutics that target the c...
![](https://cdn.snapi.dev/images/v1/j/p/press3-1941962.jpg)
InflaRx Announces Commercial Launch of Gohibic (vilobelimab) in the U.S. for the Treatment of Critically Ill COVID-19 Patients
JENA, Germany, June 21, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today ...
![](https://cdn.snapi.dev/images/v1/v/d/press6-1891589.jpg)
WuXi Biologics Announces Manufacturing Partnership with InflaRx to Advance Gohibic for the Treatment of Certain Critically Ill COVID-19 patients
WuXi Biologics is the manufacturing partner of InflaRx for Gohibic (vilobelimab), a first-in-class monoclonal anti-C5a antibody. InflaRx received emergency use authorization (EUA) from the FDA for Goh...
![](https://cdn.snapi.dev/images/v1/w/r/press4-1884746.jpg)
InflaRx Reports First Quarter 2023 Financial and Operating Results and Provides Business Update
JENA, Germany, May 11, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today f...
![](https://cdn.snapi.dev/images/v1/f/k/press18-1842350.jpg)
InflaRx Announces Closing of the Full Exercise of Greenshoe Option Increasing the Proceeds of the Recently Announced Public Offering of Ordinary Shares to US$46 million
JENA, Germany, April 18, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the com...
![](https://cdn.snapi.dev/images/v1/k/b/press15-1838250.jpg)
InflaRx Announces Closing of $40 Million Public Offering of Ordinary Shares
JENA, Germany, April 14, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the com...
![](https://cdn.snapi.dev/images/v1/g/i/press8-1833501.jpg)
InflaRx Announces Pricing of $40 Million Public Offering of Ordinary Shares
JENA, Germany, April 12, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the com...
![](https://cdn.snapi.dev/images/v1/o/a/press19-1833203.jpg)
InflaRx Announces Public Offering of Ordinary Shares
JENA, Germany, April 11, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the com...
![](https://cdn.snapi.dev/images/v1/y/7/press8-1825687.jpg)
InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients
JENA, Germany, April 04, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, ...
![](https://cdn.snapi.dev/images/v1/j/h/press18-1807432.jpg)
InflaRx Reports Full Year 2022 Financial and Operating Results
JENA, Germany, March 22, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, ...